AXTI's AI Plumbing Story Isn't Over-This Pullback May Be the Market Fixing a Bigger Mistake

AXTI is being judged on demand durability, not just AI hype

This is less an AI-bubble argument than a basic reality check. AXTI sits in the hidden backbone layer of the AI buildout - not the flashy chip names everyone knows, but the spine and circulatory system and the valves that connect them. Bulls see what should matter: demand is finally showing up in reported results. AXTI just posted record Q2 revenue of US$47.6m, up from US$17.974m a year earlier, and swung back to profit with basic EPS of US$0.1817. Bears look at the chart and argue the market got there too fast, after AXTI surged over 1,500% in six months.

The why-now is simple. After that move, the stock is now down 35% over the past month. That split is the story. One camp sees a hype trade unwinding. The other sees expectations being reset after a strong demand signal ran into real supply and capacity limits. The core question is whether customers actually need more of what AXTI makes. If they do, this pullback may be the market correcting a bigger mistake. If not, elevated expectations can still crush the stock.

Q2 results suggest real customer demand, not just a good quarter

Revenue mix and margins are the first tell

If you want to test whether this demand is real, start with where the revenue came from. Of AXTI's record $47.6 million in Q2 revenue, about $30.7 million came from indium phosphide. Management said that business reached a historical high driven primarily by data center demand.

The more important signal was profitability. In the same quarter, AXTI's non-GAAP gross margin rose to 45.0% from 29.9% in the prior quarter. That kind of jump usually points to stronger volume and mix, which is harder to fake than a one-quarter revenue spike. In practical terms, tight demand often shows up in margins before it shows up as a clean long-term narrative.

Capacity expansion is the next test

Demand only matters if AXTI can ship more. That is why the capacity plan matters. AXTI says it plans to lift quarterly indium phosphide capacity to about $60 million by year-end 2026, with a longer-term target of roughly $130 million by the end of 2027. It also disclosed a backlog above $100 million. That is the setup bulls want to see: customer demand first, then investment to unlock more shipments.

The company also has the cash to test that plan. AXTI completed a $632.5 million capital raise to support Tongmei's indium phosphide capacity expansion and fund R&D in products such as 6-inch indium phosphide. After that offering, it said it ended the quarter with $749 million in cash and investments.

Customer commitments matter more than momentum

The next check is whether customers are willing to reserve supply. They are. AXTI secured multi-year indium phosphide commitments from Lumentum, backed by up to US$87.5 million in deposits applied as shipment credits. It also signed long-term supply agreements with Casela, Coherent, and Lumentum, including $47.7 million in wafer prepayments. That looks more like buyers protecting supply chains than investors simply chasing a headline.

If those signals hold, the next rerating path is straightforward: more shipments at better margins, with customers less likely to shop elsewhere.

Why AXTI still faces a high bar at a $3.1 billion valuation

The market is now testing execution, not just the story

At roughly a $3.1 billion market cap, investors are no longer paying for a lab story. They are paying for scaled output, better mix, and repeatable execution. Yes, demand for indium phosphide substrates substantially exceeded supply, and management has outlined a path to about $60 million of quarterly InP capacity by year-end 2026. But the market is asking a practical question: can AXTI turn that demand into steady shipments without becoming a perpetual financing project?

Dilution remains the main irritant

The sharper bear case is capital structure. Earlier this spring, AXTI announced a public common stock offering, which raised immediate dilution concerns. That followed a proposal to increase authorized shares from 70 million to 120 million, reinforcing the impression of repeated equity raises. The strategic case is understandable: the company said the raise would support Tongmei's indium phosphide capacity expansion, R&D, and working capital. But investors can acknowledge demand and still hesitate if each step forward means more shares outstanding.

There is also a reason for caution on profitability. AXTI's operating income LTM remains negative, and operating margin LTM is -12%. That does not invalidate the bull case, because capacity expansion can pressure reported margins before it helps them. But it does mean skeptics still have a fair basis to demand proof.

What would validate a higher valuation

This is not a stock to chase on headlines. It is one worth watching closely because the demand signal is now visible in revenue, margins, and customer commitments. If expansion translates into consistent shipments and stronger earnings quality, today's pullback could look like a reset rather than a final verdict on the story.